Beacon Discovery proclaims multi-year GPCR drug discovery partnership with Takeda
Beacon Discovery asserted the formulation of a multi-year drug discovery collaboration with Takeda Pharmaceutical Company aiming to develop G-protein coupled receptors paving way for its role in pathology of gastrointestinal disorders.
Sunny Al-Shamma, Beacon’s CEO said “Takeda’s world class R&D organization and outstanding disease area expertise will help us realize our goal to discover first-in-class medicines.”
The agreement grants Takeda worldwide rights to develop, manufacture and commercialize products resulting from the collaboration